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Human prion diseases have inherited, sporadic, and acquired etiologies. The appearance of the novel acquired
prion disease, variant Creutzfeldt-Jakob disease (vCJD), and the demonstration that it is caused by the same prion
strain as that causing bovine spongiform encephalopathy, has led to fears of a major human epidemic. The etiology
of classical (sporadic) CJD, which has a worldwide incidence, remains obscure. A common human prion-pro-
tein–gene (PRNP) polymorphism (encoding either methionine or valine at codon 129) is a strong susceptibility
factor for sporadic and acquired prion disease. However, a quantitative-trait–locus study of prion incubation periods
in mice has demonstrated an important factor that is close to Prnp but is independent of its coding sequence or
that of the nearby prion-like doppel gene (Prnd). We have analyzed the PRNP locus for such tightly linked sus-
ceptibility factors. Fifty-six polymorphic sites have been identified within 25 kb of the PRNP open reading frame,
including sites within the PRNP promoter and the PRNP 3′ untranslated region. These have been characterized in
61 Centre d’E´tude du Polymorphisme Humain (CEPH) families, demonstrating extensive linkage disequilibrium
around PRNP and the existence of 11 major European PRNP haplotypes. Haplotype frequencies estimated in
healthy U.K. control individuals were very similar to those deduced in the CEPH families. A common haplotype
was overrepresented in patients with sporadic CJD (sCJD). Through use of a log-linear modeling approach to
simultaneously model Hardy-Weinberg and linkage disequilibria, a significant independent association was found
between sCJD and a polymorphism upstream of PRNP exon 1 ( ), in addition to the strong susceptibilityPp .005
conferred by codon 129 ( ). However, although our sample size was necessarily small, no association58Pp 2 # 10
was found between these polymorphisms and vCJD or iatrogenic CJD, in keeping with their having distinct disease
mechanisms. In addition, there was no evidence of a PRNP founder effect in the first reported geographical cluster
of vCJD.
Introduction
The appearance of variant Creutzfeldt-Jakob disease
(vCJD), which is caused by the same prion strain as that
causing bovine spongiform encephalopathy (BSE) (Col-
linge et al. 1996b; Bruce et al. 1997; Hill et al. 1997),
has led to fears of a major human epidemic (Collinge
1999). There are three well-documented episodes of hu-
man population exposure to infectious prions: admin-
istration of prion-contaminated cadaver-derived growth
hormone, the epidemic of kuru (MIM 245300) in Papua
New Guinea, and, more recently, exposure of the Eu-
ropean population to BSE-contaminated material. An
extraordinarily wide range of incubation periods has
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been observed in these episodes (Collinge 1999; Brown
et al. 2000). In the case of the kuru epidemic, with which
we have the longest experience, there are some individ-
uals who appear to be completely resistant to prion dis-
ease, despite numerous exposures, and there is a range
in the incubation period, in those affected, of 5 years to
140 years (Collinge 1999). The determinants of this var-
iability in susceptibility and incubation time are not well
understood.
A common human prion-protein–gene (PRNP [MIM
176640]) polymorphism, encoding either methionine or
valine at codon 129, is a strong susceptibility factor for
prion disease. Methionine homozygotes comprise 37%
of the U.K. population, whereas valine homozygotes
comprise 12% (Owen et al. 1990). Patients with spo-
radic CJD (sCJD [MIM 123400]) are predominantly
methionine or valine homozygotes (Palmer et al. 1991),
whereas all patients with vCJD to date have been me-
thionine homozygotes (Collinge et al. 1996a; Zeidler et
al. 1997). Valine-homozygous individuals are more sus-
ceptible to iatrogenic growth hormone–associated prion
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disease (Collinge et al. 1991). The age at onset of six-
octapeptide–repeat insertion prion disease is earlier for
methionine homozygotes, compared with heterozygotes
(Baker et al. 1991; Collinge et al. 1992). Homozygotes
of either allele have a shortened incubation period for
kuru (Cervenakova et al. 1998).
Recent evidence points to genetic susceptibility fac-
tors near mouse Prnp, independent of its coding se-
quence or that of the nearby Prnd gene. A quantitative-
trait–locus (QTL) mapping study of inbred mouse
strains has identified a region of chromosome 2, en-
compassing Prnp, as one of three major QTLs that de-
termine prion-disease incubation time after intracere-
bral inoculation with mouse-adapted scrapie (Lloyd et
al. 2001). It has been known for some time that trans-
genic mouse models with additional copies of Prnp dem-
onstrate an inverse correlation between PrP expression
level and incubation time (Prusiner et al. 1990). Sus-
ceptibility factors for human prion disease might there-
fore include sequence variation in the PRNP promoter
or variation in another tightly linked regulatory region.
There is, as yet, no evidence that sequence variation in
the recently identified PRND (MIM 604263) gene, sit-
uated 25 kb downstream of PRNP, plays any role in
prion-disease pathogenesis (Mead et al. 2000; Peoc’h et
al. 2000). However, the extent of linkage disequilibrium
(LD) at the locus is not known, potentially complicating
the assessment of individual polymorphisms.
Material and Methods
Samples
CEPH family samples were obtained from the Foun-
dation Jean Dausset, Paris. Variant, sporadic, and iat-
rogenic CJD samples were obtained from patients seen
at the U.K. National Prion Clinic, St. Mary’s Hospital,
London. All cases of sporadic and vCJD were neuro-
pathologically confirmed. DNA was extracted from ei-
ther blood or brain tissue, by use of commercially avail-
able kits. Chimpanzee (Pan troglodytes) blood was
provided by the Institute of Zoology, London. Informed
consent was obtained for all patient samples used in the
study. The St. Mary’s Hospital Ethics Committee gave
ethical approval.
Single-Nucleotide Polymorphism (SNP) Identification
SNPs of the PRNP locus were detected by automat-
ed fluorescent sequencing of samples from eight CEPH
parents (133101, 133102, 136201, 136202, 134701,
134702, 1329401, and 1329402). A single chimpan-
zee was also sequenced. Initially, the available human
genomic sequence was derived from a 35-kb clone
(GenBank accession number U29185) centered on PRNP,
over which 32 kb was sequenced in eight CEPH parents.
Subsequent to flanking genomic sequence becoming avail-
able (GenBank accession number AL133396), an addi-
tional 3 kb was resequenced in the intergenic region be-
tween PRNP and PRND, including the PRND open
reading frame (ORF) (situated 25 kb 3′ to the PRNP
ORF). A large number of individuals (16 CEPH parents
and 180 patients with prion disease) have been sequenced
for PRNP exon 1 and the PRNP promoter (750 to
240, relative to transcription start site), as well as for
PRNP exon 2, including the entire 3′ UTR. Primers were
designed to amplify PCR products that were 800–1,050
bp in length; the oligonucleotide sequences and conditions
are available on request. PCR, product purification, and
sequencing were performed in a 96-well format (96-well
plates supplied by Anachem). PCR products were purified
using a 96-well QIAGEN PCR-purification kit. The se-
quencing reaction was performed with Perkin Elmer Big
Dye Sequence Terminator Ready Reaction Mix. The re-
sulting sequencing products were washed with 70% eth-
anol and were then precipitated in 95% ethanol. Precip-
itated sequencing products were then resuspended in 2 ml
of formamide loading buffer and were denatured for 2
min, before electrophoresis on a denaturing 4.2% acryl-
amide gel (Sequagel XR, National Diagnostics) on an ABI-
377 automated sequencer for 9 h. Electropherogram
traces were visually compared, to identify SNPs in het-
erozygous individuals. Fifty-six SNPs were characterized
and were designated according to their position on clone
U29185 or on clone AL133396 (in which case the po-
sition is prefixed with “a”); the relative locations are
shown in figure 1. SNPs at sites of particular interest were
given specific names; for example, ORF polymorphism
PRNP M129V, an SNP that is 31 bp 5′ to PRNP exon
2, was designated “31,” and a PRNP 3′ UTR SNP was
designated “881.”
SNP Genotyping
Eleven of fifty-six SNPs (shown in boldface type in
fig. 1) were genotyped in 652 individuals from the CEPH
families (parents, all available grandparents, and at least
four children from each of the 61 families), to determine
SNP phase in each of the 244 CEPH founder chromo-
somes. The 11 SNPs were chosen for genotyping because
they were highly polymorphic, were evenly distributed
across the region of interest, and altered a convenient
restriction digest site. New primers were designed to am-
plify PCR products of ∼200–400 bp, including the SNP.
Restriction digests (enzymes supplied by New England
Biolabs or by Roche) were performed in a 20-ml reaction
volume by use of 2–5 ml of neat PCR product. Digested
PCR products were electrophoresed on agarose gel at 3
V/cm and were stained with 100 ng/ml ethidium bromide
in a 3#96-well format. Genotyping reactions at six sites
(13436, 16987, PRNP M129V, 28878, 34296, and
Figure 1 Line drawing of the PRNP-PRND locus, including the location of SNPs relative to PRNP exons 1 and 2
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PRND M174T) were internally controlled for failure to
digest with an invariant restriction site found near the
SNP. Genotypes for the 11 SNPs were also determined
for unrelated patients with prion disease (43 with vCJD,
93 with sCJD, and 32 with iatrogenic CJD).
Subsequently, to estimate the degree of LD in regions
flanking the PRNP haplotypes (nucleotide positions
[nps] 1368–28878 on clone U29185), 17/56 SNPs were
genotyped in the 122 CEPH parents, either by restriction
digest or by automated sequencing. Genotyping of at
least one child in each family determined the phase re-
lationship between these 17 SNPs and the known hap-
lotypes. Finally, 23/56 SNPs, all located within the re-
gion of PRNP haplotypes (nps 1368–28878 on clone
U29185), were genotyped in a selection of 20 CEPH
individuals, 9 patients with vCJD, and 2 patients with
sCJD. This genotyping was performed to determine
whether the PRNP haplotypes might be significantly
subdivided when all SNPs were considered.
Statistical Genetic Analysis
Pairwise LD was assessed for all combinations of the
26 SNPs genotyped in all CEPH founders. D′, a measure
of LD, was calculated using the DNA Sequence Poly-
morphism program (Rozas and Rozas 1999). Strong LD
facilitated the deduction of haplotypes between np 1368
and np 28878. Haplotypes were estimated in the U.K.
control samples by empirical allocation based on the
CEPH haplotype frequencies compatible with the ge-
notype data for each individual. An analysis using an
estimation-maximization (EM) algorithm gave similar
results in the two control samples (data not shown).
Since the prion-disease groups displayed marked Hardy-
Weinberg disequilibrium at most of the markers, EM
algorithms may not produce reliable results. Haplotypes
of the prion-disease samples were therefore estimated
empirically on the basis of haplotype frequencies that
were found in the U.K. control group. Comparisons of
haplotype counts in control and patient groups were
made using standard contingency-table methods (Agresti
1990).
To test for independent associations between SNPs
and prion disease, distinct from hitchhiking effects with
codon 129, a series of log-linear two-locus models were
fitted to joint genotype counts in patients and control
individuals (Weir and Wilson 1986; Tiret et al. 1991;
Weir 1996). Through use of the parameter nomencla-
ture introduced by Weir (1996), each pair of markers,
A and B, was fitted, in a series of nested models, with
parameters to model allele frequencies (MA and MB),
Hardy-Weinberg disequilibria (MAA and MBB), linkage
disequilibria (SAB and QAB), and trigenic disequilibria
(MAAB and MABB); a separate set of parameters is spec-
ified for the patients and control individuals. The sat-
urated model, therefore, includes eight parameters to
model the nine joint genotype counts that can be dis-
tinguished (i.e., quadrigenic disequilibria were unde-
fined). Models were fitted using an Excel spreadsheet
(Microsoft), which is available from the authors on
request; log likelihoods were maximized numerically
through use of the “Solver” function, and multiple in-
itial parameter values and alternative “Solver” settings
were used to reduce the possibility of accepting lo-
cal—rather than global—function minima. The good-
ness-of-fit of nested models was evaluated using like-
lihood-ratio tests with reference to x2 distributions with
degrees of freedom equal to the difference in the num-
ber of parameters being estimated.
Results
Identification of SNPs
Fifty-six SNPs were identified in the eight CEPH
parents (figs. 1 and 2; table 1), including one triallelic
SNP and one single-base–insertion polymorphism. As
expected, transitions (39/54) outnumbered transver-
sions (15/54). Twenty-two SNPs occurred at mutation
hot-spot motifs: eighteen were at CpG sites, two were
in mononucleotide runs that were more than four bas-
es long, and two were at DNA polymerase a-arrest
motifs.
Characterization of SNP Haplotypes
Strong LD was observed between all SNPs identified
between np 1368 and np 29869 (designated by their
location on clone U29185). 483c was found on a pro-
portion of all methionine haplotypes, and 34296g was
found on a proportion of all major haplotypes. These
two polymorphic sites, therefore, marked the boundaries
of the PRNP haplotypes (fig. 2). Between PRNP and
PRND, a second region of strong LD developed, com-
prising 10 SNPs extending over 12 kb of genomic se-
quence. This region of LD is delimited in the 3′ direction
by a polymorphism near the putative PRND transcrip-
tion start site (a56401). Farther 3′, within the PRND
gene, the common PRND ORF polymorphism, M174T,
and the 3′ UTR polymorphism (38 bp 3′ to M174T) are,
unsurprisingly, in strong LD with each other but not
with the intergenic haplotypes. These neighboring areas
of strong LD are illustrated in figure 3, which shows
plotting of D′ between pairs of SNPs.
In the region of strong LD around PRNP, between np
1368 and np 29686, 34 SNPs were identified. Nine of
these SNPs (shown in boldface in fig. 1) were used for
haplotyping in all the CEPH families. There was no
phase ambiguity in any family. The PRNP haplotypes
were empirically placed into 11 groups (fig. 2). Rare
haplotypes—which were identical, except for a substi-
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Figure 2 Haplotype table of the CEPH parents and CEPH grandparents (nontransmitted haplotypes only). Two bases at a single site
separated by a slash (/) indicates that there were rare haplotypes in which the second of the two bases shown was found. An asterisk (*)
indicates identity with the chimpanzee base. Suspected substitutions are shown in orange. B p most common haplotype with methionine
at codon 129, shown in yellow. Dp methionine haplotype with a guanine substitution at np 12533, near the PRNP promoter, and thymine
at np 28090, near the PRNP 3′ UTR; this haplotype may have been generated by the substitution of guanine at np 12533 on an F (483c)
haplotype. E p methionine haplotype similar to B, without substitutions at np 1368 and np 10870 and without the promoter substitution
at np 12533 but including the substitution at np 483 that is not found on valine haplotypes; alternatively, E may be a recombinant between
B and A, with a break point between np 10870 and np 13436, but here one must account for the presence of cytosine at np 483, only
found on methionine haplotypes. U and F p uncommon methionine haplotypes similar to E but with 5′ substitutions; E and F were not
distinguished in CEPH grandparents, and therefore the frequencies are combined. E was found in 15 CEPH parents, and F was found in
5 CEPH parents. K and R p two methionine haplotypes whose origin could be best explained by a single 5′ recombination event between
A and B; these haplotypes were probably generated by different but nearby recombination break points. In the case of R, the recombination
may have occurred on a D or F haplotype with 28090t, with the breakpoint between np 16987 and np 18284; in the case of K, the 5′
recombinant chromosome was probably a rare subset of A, with a substitution of 6266c and a breakpoint between np 13426 and np 13934.
A p most common haplotype with valine at codon 129, shown in green. Gp valine haplotype similar to A in the 5′ direction from M129V
but similar to B in the 3′ direction from M129V. Lp valine haplotype, which, like Q below, has a pattern of SNPs similar to the chimpanzee;
also found are substitutions unique to this haplotype, including the A117A PRNP ORF silent polymorphism, a polymorphism 31 bp 5′ to
the PRNP translation start site (31), and a common PRNP 3′ UTR polymorphism 881 bp 3′ to the PRNP translation start site (881),
shown in purple. Q p valine haplotype, similar to L and, again, with a number of substitutions found only on this haplotype, shown in
blue (nps 5039, 10434, 16713, 18284, 18365, and 31290). Only 8/244 haplotypes, all on valine chromosomes, each found in one parental
chromosome only, could not be placed in one of these eight haplotypes. These are not shown.
tution at a single site, to a more common haplo-
type—were also included in the larger group. The likely
nucleotide substitution at each site was predicted by
comparison with the chimpanzee sequence.
The two most common haplotypes, A (valine) and B
(methionine), representing 155% of the total haplotype
diversity, are opposite in state at all highly polymorphic
loci. This suggests that the northern European PRNP
genealogy is characterized by two major branches. Hap-
lotypes Q and L are remarkable in that their patterns
of SNPs are strikingly similar to that observed in the
chimpanzee, with the exception of a substitution of val-
ine for methionine at PRNP codon 129. This chimpan-
zee haplotype pattern, together with a number of nu-
cleotide substitutions found only on haplotypes Q and
L, suggests that these two uncommon haplotypes also
represent deep branches of the PRNP genealogy. 5′ re-
combination events of A on B were assumed to have
generated haplotypes K, R, and, possibly, U and E, since
these haplotypes change state from being like an A hap-
lotype to being like a B haplotype, at a single putative
ancestral recombination break point. Recombinant hap-
lotypes were observed on methionine haplotypes, but
none of the complementary recombinant haplotypes
were observed on a valine haplotype.
To test whether the above haplotypes of 9 SNPs be-
tween np 1368 and np 29869 were representative of
the true haplotype diversity in the CEPH families, an
additional 23 SNPs in the interval between np 1368
and np 29869 were genotyped in a collection of 20
CEPH individuals chosen to represent the previously
established haplotype diversity. SNPs at np 16731, np
28090, and np 29869 were genotyped and phased in
all CEPH parents. The extra genotypes in the additional
individuals were consistent with the previously estab-
lished groups of haplotypes, demonstrating the validity
of the restricted SNP set. Only two new haplotypes
were generated by the additional genotyping: a variant
Table 1
SNPs Identified
Namea SNPb
Method of
Genotypingc
No. of CEPH
Chromosomes
Genotypedd
Frequency of
Uncommon
Allele
(%)
483 c/T SfcI 244 19
1368 C/t PvuII 652 35
2006 a/g Sequencing 16 Singleton
2537 G/t ItaI 44 50
5039 T/a MaeII 48 4
6262 A/g XmnI 62 8
10017 c/g Sequencing 14 Singleton
10434 c/t Sequencing 44 5
10870 g/A Tsp509I 652 36
12071 a/g DGGE 80 2
12533 c/G BstNI 652 13
13017 t/c Sequencing 42 Singleton
13436 T/c PstI 652 42
13934 T/g TfiI 42 31
16712 t/c Sequencing 40 5
16831 t/G BstNI 244 39
16987 G/t AluI 652 35
17881 a/g Sequencing 44 39
17913 c/t Sequencing 44 39
18284 c/t Sequencing 38 5
18365 g/a Sequencing 38 5
18422 a/G MaeII 652 37
21587 a/g Sequencing 44 34
21817 insert A Sequencing 44 34
22699 g/a Sequencing 48 38
22814 t/c Sequencing 44 41
22976 a/G AccI 652 30
31 g/a Sequencing 160 4
A117A A/g PvuII 160 4
M129V A/g NspI 652 38
881 g/a Sequencing 160 4
28090 c/T AluI 244 25
28779 t/a Sequencing 48 33
28878 C/t AluI 652 23
29869 a/T Tsp509I 244 28
31290 a/C PvuII 48 4
32709 a/g Sequencing 48 4
34296 a/G HincII 652 36
34819 t/C RsaI 48 10
34970 t/c Sequencing 48 Singleton
35001 g/c Sequencing 48 6
a64644 g/c Sequencing 42 14
a64543 t/C HpyCH4IV 244 19
a61397 c/t Sequencing 244 22
a61329 c/t Sequencing 244 22
a61277 c/t Sequencing 244 18
a61251 a/g Sequencing 244 18
a61140 c/a Sequencing 244 22
a61047 g/t Sequencing 244 Singleton
a60989 c/g/a Sequencing 244 15/8
a56401 C/g Eco57I 244 9
PRND T26M c/t Sequencing 244 2
PRND P56L c/t Sequencing 244 1
PRND M174T c/T NlaIII 652 48
PRND T174T a/g Sequencing 244 1
PRND UTR t/c Sequencing 244 49
a Name corresponds with the location of the SNP on U29185 (no prefix) or on AL133396
(prefixed by “a”).
b The nucleotide to the left of the slash was the more frequent allele; the nucleotide
denoted by a capital letter is the allele that is cut by the restriction enzyme shown in the
“Method of Genotyping” column.
c DGGE p Denaturing gradient gel electrophoresis.
d 244 p Genotyping of all CEPH parents and at least one child, to experimentally
determine SNP phase in the parents.
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Figure 3 Table of pairwise D′ (calculated using DNAsp), showing pairwise LD between SNPs
of haplotype E, with 2537g and 28090t, found in 5/
244 haplotypes (designated “haplotype F”), and a var-
iant of haplotype B, with 16831g, found in 1/244
haplotypes.
Association Study
Prion-disease samples (43 vCJD, 95 sCJD, and 32 iat-
rogenic CJD) were genotyped at 11 sites, including the
9 SNPs used to define PRNP haplotypes in the CEPH
families, shown in boldface type in figure 1. Haplotype
frequencies determined in the CEPH families, together
with estimated haplotype frequencies from the U.K. con-
trol population, from the patient group with sCJD, and
from the patient group with vCJD, are shown in table
2. There is no significant difference in haplotype fre-
quencies between the CEPH families and U.K. control
population ( ). Haplotype frequencies in thePp .89
prion disease groups are very different from both control
populations (e.g., CEPH vs. sCJD, ; CEPH4Pp 4 # 10
vs. vCJD, ). The haplotype distribution is mark-6P ! 10
edly skewed toward methionine haplotypes, a pattern
predicted by the reported susceptibility to prion diseases
that is associated with the M129V polymorphism. The
strongest effect of M129V in sCJD is the resistance to
prion disease shown by heterozygotes (table 3; 2x p
, ). In combination with the strong LD at21.6 P ! .0001
the PRNP locus, this leads to a striking Hardy-Weinberg
disequilibrium in the prion-disease groups, at all sites
between np 1368 and np 28878. It is therefore necessary
to model Hardy-Weinberg disequilibrium and LD be-
tween markers, to assess the independent statistical as-
sociation of polymorphisms at PRNP. It is important to
differentiate between those markers that associate with
prion disease because of a hitchhiking effect with codon
129 and alleles that are independent prion-disease–
susceptibility factors. We applied a log-linear two-locus
modeling approach, to tackle this problem (Weir and
Wilson 1986; Tiret et al. 1991; Weir 1996) in a joint
genotype analysis of a test SNP and M129V (Tiret et al.
1991), comparing genotype frequencies in patients with
sCJD and in CEPH founders. There was no evidence of
trigenic disequilibria in the analyses of SNP 1368 with
M129V (table 4; comparison of models 1 and 2, Pp
). There was also no evidence ( ) of Hardy-.84 Pp .67
Weinberg disequilibrium in the case or control groups
at SNP 1368, nor was there evidence of Hardy-Weinberg
disequilibrium in the control group at M129V, and iden-
tical patterns of LD were consistent in the case and con-
trol groups (comparison of models 1 and 3). This par-
simonious model (model 3) was compared with nested
model 4, in a likelihood-ratio test of the independent
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Table 2
Estimated Haplotype Frequencies in Case and Control Groups
HAPLOTYPE
FREQUENCY (%) INa
CEPH
Individuals
( )np 412
U.K. Control
Population
( )np 190
Patients with sCJD
( )np 186
Patients with vCJD
( )np 86
B 148 (35.7) 70 (36.8) 100 (53.8) 50 (58.1)
D 48 (11.6) 22 (11.6) 18 (9.8) 12 (13.9)
E/Fb 39 (9.4) 19 (10.0) 15 (8.1) 17 (19.7)
K 13 (3.1) 7 (3.7) 4 (2.1) 2 (2.3)
R 5 (1.2) 0 3 (1.6) 3 (3.5)
U 5 (1.2) 1 (0.5) 0 0
Other M 4 (1.0) 2 (1.1) 6 (3.2) 2 (2.3)
A 79 (19.0) 34 (18.4) 27 (14.5) 0
G 27 (6.5) 10 (5.3) 4 (2.1) 0
L 16 (3.9) 9 (4.7) 1 (0.5) 0
Q 13 (3.1) 6 (3.2) 6 (3.2) 0
Other V 15 (3.6) 10 (5.3) 2 (1.1) 0
a In the CEPH founders, phase assignments were unambiguously deduced in genotyped families; in the other
groups, assignments were deduced by empirical allocation based on frequencies determined in control populations.
b E and F could not always be distinguished in the disease groups, and, therefore, a combined total is shown.
association between the cytosine allele at SNP 1368 and
sCJD ( , 1 df, ). A comparison of hi-2x p 7.9 Pp .005
erarchical models 2 and 5 provides a test for the inde-
pendent association between M129V and susceptibility
to sCJD ( , 6 df, ). Similar results2 8x p 47.1 Pp 2 # 10
were found in a complementary analysis of the patients
with sCJD and 269 healthy white individuals from the
U.K. population (table 3); SNP 1368 was found to be
independently associated with the risk of developing
sCJD ( ). 1368c is nearly always found on aPp .003
129M chromosome (haplotype B), and, therefore, we
propose that this haplotype is associated with sporadic
prion disease. Since 1368c is very rarely coupled with
129V (only one 1368c 129V haplotype in patients with
sCJD), the association applies to methionine-homozy-
gous sCJD. Analysis of variance indicated that there was
no difference in age at onset of disease or in disease
duration between the three genotypes at SNP 1368. All
other sites, including SNP 34296 and PRND M174T,
showed no independent evidence of association once the
association at M129V had been modeled (data not
shown).
Founder Haplotypes
A cluster of vCJD near the Leicestershire village of
Queniborough in the United Kingdom has been inves-
tigated for local environmental risk factors (Cousens et
al. 2001). An alternative hypothesis is that a rare PRNP
vCJD-susceptibility allele is found at a high frequency
in this locality, because of a founder effect, with the allele
occurring recently enough to be geographically localized
but not so recently that family relationships may be read-
ily identified. Three samples from patients with vCJD
from the Leicestershire cluster were available for this
study. The individual genotype combinations in these
three individuals were incompatible with a shared PRNP
susceptibility allele.
Discussion
We have sequenced 35 kb of the PRNP locus, to identify
informative SNPs in the northern European population.
This was followed by RFLP analysis of the CEPH fam-
ilies, to build a haplotype table of a region of strong LD
around PRNP. In the northern European population,
PRNP haplotypes with methionine at codon 129 were
characterized by a 10-kb region of complete LD around
the PRNP ORF. 5′ substitutions and multiple presumed
recombination events between the common A and B
haplotypes provided the haplotype diversity. The hap-
lotypes with valine at codon 129 were more diverse than
those with methionine at codon 129, with the uncom-
mon Q and L haplotypes being very similar to the chim-
panzee haplotype. We have found a significant associ-
ation between a PRNP upstream polymorphism and
sCJD, by genotyping 168 patients with prion disease of
different etiologies.
The etiology of sCJD remains obscure; it is possible
that some cases result from environmental exposure to
prions, but this mechanism is unlikely, on epidemiolog-
ical grounds, to explain the majority of cases (Brown
et al. 1987). Alternative possibilities include a stochastic
conversion of normal prion protein to the infectious
form or a somatic PRNP mutation leading to a cell or
cluster of cells that translate a mutant prion protein
predisposed to convert to an infectious prion. Haplo-
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Table 3
Joint Genotype Table at Sites 1368 and M129V
GENOTYPE
(1368/M129V)
FREQUENCY IN
AGE AT
ONSET
(RANGE)
(years)
MEDIAN
DISEASE
DURATION
(RANGE)
(mo)
CEPH
Individuals
U.K. Control
Population
Patients
with
sCJD
tt/vv 25 31 15 57 (37–77) 6 (2–15)
ct/vv 4 3 1 58 4
cc/vv 0 0 0 … …
tt/mv 34 55 3 65 (61–65) 7 (3–11)
ct/mv 59 60 5 71 (47–79) 14 (2–23)
cc/mv 1 0 0 … …
tt/mm 14 23 4 63 (56–79) 2 (1–3)
ct/mm 45 51 29 69 (43–86) 3 (1–22)
cc/mm 23 46 36 66 (41–83) 3 (1–17)
Total 205 269 93
type association could act through enhanced expression
of PRNP, which fits most easily with a hypothesis of
stochastic protein misfolding. High levels of expression
of PRNP may make the initial conversion of PrPc to the
infectious form more likely. One might expect altered
disease phenotypes with overexpression; however, no
major differences were seen in age at onset or in du-
ration of disease, when analyzed by polymorphism. This
dissociation of disease susceptibility and phenotype sug-
gests that different biological mechanisms account for
these variables. Factors such as PrPSc strain type and
variation of other genes affecting disease pathways may
have a greater role in the generation of variation in
clinical phenotypes.
In regard to the potential confounding variable of
population stratification, there are numerous genotyp-
ing studies of the codon 129 polymorphism in Europe,
including studies in France, Germany, Italy, Spain, and
the United Kingdom (Owen et al. 1990; Salvatore et
al. 1994; Berr et al. 1998; Windl et al. 1999; Zim-
mermann et al. 1999). There is a very small range of
valine allele frequencies in these countries (0.348–
0.377). Additionally, there were no significant differ-
ences between estimated haplotype frequencies or al-
lele frequencies at 11 SNPs, genotyped in 95 U.K.
blood donors and the CEPH families. An association
between 1368c and sCJD was demonstrated with ei-
ther the CEPH families or the healthy U.K. population
used as a control group.
Geographical and temporal coincidence, together
with molecular and biological strain-typing studies,
have clearly linked the etiology of vCJD with the epi-
demic of BSE in the United Kingdom (Collinge et al.
1996b; Bruce et al. 1997; Hill et al. 1997). The extent
of human genetic susceptibility to BSE prions in the U.K.
population is not only important for modeling the po-
tential size of the epidemic of vCJD in the future but
also for identifying high-risk individuals who might be
in a presymptomatic phase of illness. Such individuals
could be targeted, should a treatment become available,
and they represent a risk of potential transmission of
human prions via blood transfusion or surgical instru-
ments (Collinge 1999). vCJD has, so far, been diagnosed
only in those who are homozygous for methionine at
codon 129 of the PRNP ORF (Collinge et al. 1996a;
Zeidler et al. 1997). The present study shows that this
genetic association is not related to a unique suscepti-
bility haplotype, since the complete spectrum of north-
ern European methionine-haplotype diversity was ob-
served in the vCJD group. However, all methionine
haplotypes were identical over a 10-kb region, which
includes the PRNP ORF. It remains possible, therefore,
that the predilection for vCJD in methionine homozy-
gotes may be related to variation in intronic regulatory
regions, in addition to the codon 129 amino acid
change. As the epidemic of vCJD progresses, we expect
to see valine-homozygous and, later, valine-heterozy-
gous cases (Collinge 1999). If so, then the greater in-
tronic diversity of the valine haplotypes observed in the
CEPH families, including methionine-haplotype–like
bases in the PRNP intron, might allow this possibility
to be tested.
The vCJD cases to date are presumably those in in-
dividuals with both susceptibility to prion disease and
a short incubation time after exposure to BSE. It might
be expected that these individuals have not only disease-
susceptibility alleles but also short-incubation-period al-
leles, at all human prion-disease QTLs. We were unable
to demonstrate an association between PRNP poly-
morphisms and vCJD; this may relate to a lack of sta-
tistical power due to the relatively small numbers of
patients with vCJD available for analysis to date. Al-
ternative explanations of the observed variation in in-
cubation time in vCJD include a BSE dosage effect, other
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Table 4
Log-Linear Two-Locus Analysis of SNP 1368 and M129V
MODEL
PARAMETERa
DEVIANCEb
NO. OF
PARAMETERSMA1 MA2 MB1 MB2 MAA1 MAA2 MBB1 MBB2 SAB1 SAB2 QAB1 QAB2
Trigenic
Disequilibrium
1 * * * * * * * * * * * * * .00 16
2 * * * * * * * * * * * * 1 1.42 12
3 * * * * 1 1 1 * * SAB1 * QAB1 1 6.73 7
4 * MA1 * * 1 1 1 * * SAB1 * QAB1 1 14.63 6
5 * * * MB1 1 * 1 1 * SAB1 * QAB1 1 48.56 6
a Parameters MA and MB model allele frequencies—and MAA and MBB model Hardy-Weinberg disequilibrium—for the 1368 and M129V
markers, respectively. SAB and QAB model LD between alleles at the two markers. Parameters for the CEPH and sCJD strata are labeled
with subscripts 1 and 2, respectively. Trigenic disequilibrium includes two parameters, MAAB and MABB, for each stratum (cases and controls).
An asterisk (*) indicates that the parameter was estimated by maximum likelihood in the analysis. “1” indicates that the parameter was
fixed (null effect) in the analysis. Otherwise, the parameters were equated across the two strata.
b Deviance is the 2 loge-likelihood difference with saturated model 1.
unidentified environmental factors, and QTLs on other
chromosomes. There has been interest in the evident
geographical clustering of vCJD, in a village in Leices-
tershire, United Kingdom (Cousens et al. 2001), that
might reflect shared environmental and/or genetic risk
factors. There is no evidence of a PRNP founder effect
in this cluster, discounting the hypothesis that the clus-
tering may relate to a high-risk PRNP vCJD-suscepti-
bility allele.
Attention has been focused on the recently identified
prion-protein–like gene PRND, although there is no
evidence that coding variation has a role in human
prion disease (Mead et al. 2000; Peoc’h et al. 2000).
Uncommon alleles in the PRND ORF, such as P56L
and T174T, tend to occur on single extended haplo-
types, presumably reflecting their recent evolutionary
origin. An extensive region of LD was identified across
the intergenic region between PRND and PRNP. Nei-
ther the intergenic haplotype, the PRND M174T poly-
morphism, nor any of the extended haplotypes asso-
ciated with uncommon PRND alleles were associat-
ed with any prion-disease variables. Investigation of
PRND may prove to be more useful for understanding
normal prion-protein function, rather than prion dis-
ease pathogenesis.
The identification of PRNP upstream polymorphisms
that confer susceptibility to human prion disease is in
keeping with the findings of a major QTL on mouse
chromosome 2 (Lloyd et al. 2001). It should be noted,
however, that the present study does not provide evi-
dence that polymorphisms upstream of Prnp are re-
sponsible for the mouse chromosome 2 QTL. It is im-
portant that an association be tested in different human
populations, particularly those with potentially greater
intronic haplotype diversity. Further studies are under-
way to characterize a mechanism of susceptibility, by
deletion analysis in transgenic mice.
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